Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes

Epilepsia
Iris M de LangeEva H Brilstra

Abstract

Pathogenic variants in SCN1A can give rise to extremely variable disease severities that may be indistinguishable at their first presentation. We aim to find clinical features that can help predict the evolution of seizures into Dravet syndrome and clinical features that predict cognitive outcome in Dravet syndrome. We specifically investigate the role of contraindicated medication (CIM) as a possible modifier of cognitive decline. A cohort of 164 Dutch participants with SCN1A-related seizures was evaluated. Clinical data were collected from medical records and semistructured telephone interviews. Cognitive function was classified by a child neurologist, neuropsychologist, and clinical geneticist. Several clinical variables, including duration of CIM use in the first 5 years of disease, were evaluated in univariate and multivariate analyses. A longer duration of CIM use in the first 5 years after seizure onset was significantly associated with a worse cognitive outcome at time of inclusion, and with lower interpolated intelligence quotient/developmental quotient scores after the first 5 years of disease in Dravet syndrome patients. CIM use remained a significant predictor for cognitive outcome in a multivariate regression model...Continue Reading

References

May 20, 2003·Human Mutation·Lieve ClaesPeter De Jonghe
Jul 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Thomas H RhodesAlfred L George
May 10, 2005·Human Mutation·John C MulleyLouise A Harkin
Mar 10, 2007·Brain : a Journal of Neurology·Louise A HarkinIngrid E Scheffer
Jan 1, 2010·Epilepsia·Mari AkiyamaYoko Ohtsuka
Mar 3, 2010·The Journal of Physiology·William A CatterallJohn C Oakley
Jan 21, 2011·Neurology·S M ZuberiG H Forbes
Apr 8, 2011·Epilepsia·Francesca Ragona
Apr 29, 2011·Developmental Medicine and Child Neurology·Renzo Guerrini, Melania Falchi
Apr 29, 2011·Developmental Medicine and Child Neurology·Berten Ceulemans
Jul 2, 2011·Brain : a Journal of Neurology·Claudia B CatarinoSanjay M Sisodiya
Nov 5, 2011·Acta Neurologica Scandinavica·A BremerK O Nakken
Jun 22, 2012·Brain : a Journal of Neurology·A BrunklausS M Zuberi
Jul 12, 2012·Epilepsia·Jennifer J RilstoneDanielle M Andrade
Oct 30, 2012·Neurobiology of Disease·Iori OhmoriHideki Matsui
Nov 21, 2012·Developmental Medicine and Child Neurology·Andreas BrunklausSameer M Zuberi
Nov 15, 2013·Orphanet Journal of Rare Diseases·Rima NabboutCatherine Chiron
May 20, 2014·Epilepsia·Andreas Brunklaus, Sameer M Zuberi
Mar 6, 2015·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Sue RichardsUNKNOWN ACMG Laboratory Quality Assurance Committee
Jun 17, 2015·Seizure : the Journal of the British Epilepsy Association·F M Snoeijen-SchouwenaarsI Y Tan
Jun 19, 2016·Neurology·Cyril GitiauxRima Nabbout
Jan 14, 2017·Neuroscience Letters·Simona Balestrini, Sanjay M Sisodiya
Apr 5, 2017·Experimental Neurology·Stacey B B DuttonAndrew Escayg
Oct 7, 2017·Developmental Medicine and Child Neurology·Lieven LagaeAlysia Battersby

❮ Previous
Next ❯

Citations

Apr 25, 2019·Expert Review of Clinical Pharmacology·Krista Eschbach, Kelly G Knupp
May 18, 2019·Expert Opinion on Pharmacotherapy·Ganna BalaguraPasquale Striano
Jan 7, 2020·Epilepsia·J Helen CrossLieven Lagae
Feb 8, 2020·Molecular Genetics & Genomic Medicine·Iris M de LangeBobby P C Koeleman
Jul 16, 2019·Brain : a Journal of Neurology·Joseph D SymondsMargaret Wilson
Aug 18, 2020·Expert Review of Neurotherapeutics·Adam Strzelczyk, Susanne Schubert-Bast
Mar 23, 2019·Expert Review of Neurotherapeutics·Catherine Chiron
Sep 25, 2019·CNS Drugs·Elaine C Wirrell, Rima Nabbout
Oct 14, 2018·Current Treatment Options in Neurology·Julie ZiobroKelly G Knupp
May 31, 2019·Molecular Genetics & Genomic Medicine·Iris M de LangeBobby P C Koeleman
Oct 19, 2020·Practical Neurology·Katri SilvennoinenSanjay M Sisodiya
Oct 22, 2020·Epilepsia·Quratulain Zulfiqar AliDanielle M Andrade
Oct 21, 2020·Nature Reviews. Neurology·Rima Nabbout, Mathieu Kuchenbuch
Nov 25, 2020·Developmental Medicine and Child Neurology·Karen VerheyenAnn Hallemans
Dec 5, 2020·Expert Opinion on Drug Discovery·Barbara Miziak, Stanisław Czuczwar
Jan 19, 2021·Expert Review of Neurotherapeutics·An-Sofie Schoonjans, Berten Ceulemans
Jan 22, 2021·Epilepsia·Katherine B HowellA Simon Harvey
Dec 22, 2019·Seizure : the Journal of the British Epilepsy Association·Tracy S GertlerLinda Laux
Jan 1, 2020·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Elisa MustoRikke S Møller
Jan 5, 2021·Current Opinion in Neurology·Lieven Lagae
Jun 1, 2021·Epilepsy & Behavior : E&B·Norimichi HigurashiShinichi Hirose
May 23, 2021·Lancet Neurology·Nafisa HuseinJosemir W Sander
Jun 8, 2021·Seizure : the Journal of the British Epilepsy Association·Zihan WeiYanchun Deng
Nov 16, 2021·British Journal of Clinical Pharmacology·Carla Marini, Maria Giardino
Dec 10, 2021·Epilepsia Open·Elena Cardenal-MuñozJosé Ángel Aibar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.